budesonide (Pulmicort nebulizing suspension).

Phase 3Small molecule

budesonide (Pulmicort nebulizing suspension). is one of 2 small molecule programs targeting Budesonide. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

BudesonideActive, not recruiting

BudesonidePhase 3

Active, not recruiting

Competition

Competitive Landscape

2 competitors in Budesonide

#DrugCompanyPhaseTrials

budesonide (Pulmicort nebulizing suspension).

NNICHD Neonatal Research Network

Phase 3

1 2

Poractant Alfa Intratracheal

HHospital Clinic of Barcelona

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 3Active, not recruiting

Budesonide

NCT04545866

Clinical

Trials by Indication[1]

Budesonide1 trial

The Budesonide in Babies (BiB) Trial

Active, not recruiting·NNICHD Neonatal Research Network·Phase 3·NCT04545866·642 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for budesonide (Pulmicort nebulizing suspension).. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — budesonide (Pulmicort nebulizing suspension). compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for budesonide (Pulmicort nebulizing suspension).. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — NICHD Neonatal Research Network company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: NNICHD Neonatal Research Network

budesonide (Pulmicort nebulizing suspension).

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

Budesonide1 trial

References

Drug Info

Quick Facts

Related News